Evonik stock rating cut to hold by Kepler Cheuvreux

Published 19/02/2025, 12:10
Evonik stock rating cut to hold by Kepler Cheuvreux

On Wednesday, Kepler Cheuvreux adjusted its stance on Evonik Industries AG (ETR:EVKn) (EVK:GR) (OTC: EVKIF), downgrading the stock from a Buy rating to Hold and setting a price target of EUR21.00. The move comes amid a recent rally in the stock’s price, which analysts attribute to a broader market trend favoring cyclical value stocks, as well as speculative optimism regarding potential peace in Ukraine and the subsequent rebuilding efforts that could involve Evonik.

The firm’s analysts pointed out that while the market is hopeful for a reduction in gas costs and a potential boost to Evonik from the reconstruction of Ukraine, they believe any benefits to the company will be modest and may materialize later than anticipated, if at all. With the stock’s price nearing the target, Kepler Cheuvreux sees limited upside potential and has opted for a tactical downgrade, anticipating a more favorable buying opportunity in the future.

Despite the downgrade, Kepler Cheuvreux maintains a long-term positive outlook on Evonik, considering the stock to be undervalued. The analyst’s commentary suggests a cautious approach, acknowledging the current market dynamics and the uncertainty surrounding the geopolitical situation and its impact on energy costs.

Evonik Industries AG, a leading specialty chemicals company headquartered in Germany, has been part of the broader market conversation around companies that could stand to benefit from a post-conflict economic environment in Ukraine. However, the Kepler Cheuvreux analysis indicates that while there is potential, it may not be as immediate or significant as some investors hope.

The downgrade to a Hold rating reflects a wait-and-see attitude, with Kepler Cheuvreux signaling to investors that while the current situation has driven up the stock, the anticipated benefits are not sufficient to maintain a Buy rating at this time. The firm suggests keeping an eye on Evonik for a more opportune moment to invest, based on the expectation that a better entry point could present itself in the coming months.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.